Investor Relations

Investor Relations

Recent News
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026

—New Clinical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible...

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
Mar 19, 2026

─Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and...

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
Feb 17, 2026

TEL AVIV, Israel ─ February 17, 2026 ─ Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
Dec 2, 2025

—New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a Phase 3 Registration Trial— TEL...

All News

Stock Info
NASDAQCMMB
Events
EASL 2026 Congress
Saturday, May 30, 2026
8:30am - 4:00pm CEST

Abstract No. 1839
Format: Poster presentation: AI-driven proteomic profiling differentiates composite improvement following treatment with nebokitug in PSC
Presenter: Jack Lawler, Chief Development Officer, Chemomab Therapeutics
Session: Immune-mediated and cholestatic disease: Clinical aspects

Abstract No. 1852
Format: Poster presentation: Nebokitug down-regulates core fibrotic and immune pathways defined by single-cell liver profiling
Presenter: Jack Lawler, Chief Development Officer, Chemomab Therapeutics
Session: Immune-mediated and cholestatic disease: Clinical aspects

Abstract No. 1859
Format: Poster presentation: Nebokitug modulates gut-liver inflammatory and tissue remodeling signatures in PSC patients with coexisting IBD
Presenter: Jack Lawler, Chief Development Officer, Chemomab Therapeutics
Session: Immune-mediated and cholestatic disease: Clinical aspects

Information: https://www.easlcongress.eu

Digestive Disease Week 26®
Monday, May 4, 2026
2:00pm - 3:30pm CDT

Location: Chicago, USA
Format: Abstract Lecture: Nebokitug Modulates Inflammatory and Tissue-Remodeling Signatures in Patients with PSC and Coexisting IBD: Biomarker Findings from the SPRING Phase 2 Trial
Presenter: Parvez Mantry MD AGAF FAASLD
Session: Advances in the Management of Primary Sclerosing Cholangitis 
Time:  2:00-3:30pm Central Time
Information: https://ddw.org

All Events

Featured Presentations

Download

Chemomab Corporate Overview - March 2026

 

About
Chemomab Therapeutics Ltd.

Chemomab is developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from five clinical trials of nebokitug. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of a nebokitug Phase 3 trial in PSC. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s nebokitug program for the treatment of systemic sclerosis has an open U.S. IND.

Join our mission.
Collaborate with us.

Collaborate with us.

We are actively seeking strategic collaborations and licensing opportunities that align with our therapeutic areas of focus.

To explore partnership opportunities, please contact us.

Quick
Links

© Copyright 2025 Chemomab Therapeutics Ltd. All rights reserved. Privacy Policy. Terms of Use. Cookie policy.

Site Design by Michael Kulwiec DesignLab.

Site Design by Michael Kulwiec DesignLab.